Welcome to our dedicated page for Seres Therapeutics news (Ticker: MCRB), a resource for investors and traders seeking the latest updates and insights on Seres Therapeutics stock.
Seres Therapeutics, Inc. develops live biotherapeutic products and microbiome-based therapies for inflammatory, immune, infectious and gastrointestinal diseases. Company updates commonly address pipeline programs such as SER-155 for immune checkpoint inhibitor-related enterocolitis and prevention of bloodstream infections in allogeneic hematopoietic stem cell transplant patients, SER-603 for inflammatory bowel disease, and SER-428 for antimicrobial resistance and serious infections.
Recurring announcements include financial results, operational updates, research publications, scientific conference presentations, biomarker and microbiome-mechanism data, collaborations, financing and partnership activity, cost-control measures, and governance changes.
Seres Therapeutics (Nasdaq:MCRB) announced that management will present a company overview at the H.C. Wainwright 4th Annual BioConnect Investor Conference at 3:30 p.m. ET on May 19, 2026.
A live webcast and replay will be available via the company’s investor relations website.
Seres (Nasdaq: MCRB) reported Q1 2026 results and business updates on May 5, 2026. Key items: investigator-sponsored SER-155 irEC study readout expected in the coming weeks (15 patients enrolled), SER-155 Phase 2 readiness for allo-HSCT, IND-enabling work for SER-603, CARB-X–supported SER-428 development, and $29.8M cash expected to fund operations through Q3 2026.
Q1 2026 net loss was $19.9M versus net income of $32.7M in Q1 2025; R&D was $13.2M and G&A was $8.1M.
Seres Therapeutics (Nasdaq: MCRB) presented preclinical data at Digestive Disease Week 2026 supporting SER-603, a next-generation cultivated live biotherapeutic candidate for inflammatory bowel disease (IBD). The poster was selected as a DDW Poster of Distinction and highlights rational strain selection, biomarker-driven patient stratification, and IND-enabling progress.
Data show SER-603 reduced inflammatory cytokine production in a MiGUT in vitro gut model and the company reports engagement with potential collaborators to support clinical development.
Seres Therapeutics (Nasdaq: MCRB) presented Phase 1b and translational data at ESCMID Global 2026 (April 17–21). Seres reported that SER-155 induced a significant, durable shift in GI microbiome composition and was associated with improved GI epithelial barrier integrity versus placebo.
Presentations included a SER-155 poster, an oral MiGut model talk with University of Leeds collaboration, and a symposium on microbiome strategies in immunocompromised patients.
Seres Therapeutics (Nasdaq: MCRB) will present at the CARB-X Investor Day on April 16, 2026, ahead of ESCMID in Munich. Elizabeth Halvorsen, Ph.D., will overview Seres’ therapeutic platform and its CARB-X collaboration. In 2025 Seres received up to $3.6 million from CARB-X to advance SER-428, an oral liquid formulation derived from SER-155 strains, and is designing a Phase 1b open-label trial in medical ICU patients.
Seres Therapeutics (Nasdaq: MCRB) reported fourth-quarter and full-year 2025 results and business updates on March 12, 2026. Key points: clinical data from a 15-subject investigator-sponsored SER-155 study in immune checkpoint–related enterocolitis is expected in Q2 2026, SER-603 IND-enabling work continues, and the company had $45.8M cash at year-end with runway into Q3 2026.
Full-year net income from continuing operations was $5.7M, driven by lower operating expenses and installment payments from Nestle.
Seres Therapeutics (Nasdaq: MCRB) appointed Richard N. Kender as Executive Chair and Interim CEO and reorganized senior roles as it narrows focus to live biotherapeutics for inflammatory and immune diseases.
The company expects an investigator-sponsored SER-155 clinical readout in Q2 2026, reports $45.8M cash as of Dec 31, 2025, and expects runway through Q3 2026 while pursuing funding and strategic partnerships.
Seres (Nasdaq: MCRB) is pausing additional investment in the SER-155 Phase 2 allo-HSCT program after finalizing the FDA protocol and advancing startup activities, and will prioritize earlier-stage live biotherapeutic programs for inflammatory and immune diseases.
Cost-reduction measures, including ~30% workforce reduction, are expected to extend runway through Q3 2026 while the company seeks funding and pursues collaborations; SER-155 IST in irEC is fully enrolled with initial data expected early Q2 2026.
Seres Therapeutics (Nasdaq: MCRB) announced two publications in Nature Medicine and the Journal of Infectious Diseases detailing VOWST™ functional mechanism and clinical translation.
The Nature Medicine paper reported dose-related faster engraftment, shifts in gut metabolites (decreased primary/increased secondary bile acids; higher short- and medium-chain fatty acids) that inhibit C. difficile germination and growth. The Journal of Infectious Diseases analysis found similar gastrointestinal microbiome and bile acid profiles in first and multiply recurrent C. difficile patients, with comparable VOWST pharmacology and efficacy across groups.
Seres noted these MbTx platform data supported its pipeline, including lead candidate SER-155, whose randomized Phase 1b showed a 77% reduction in bacterial bloodstream infections and reduced antibiotic use in allo-HSCT patients.
Seres Therapeutics (Nasdaq: MCRB) said management will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025 at 10:30 a.m. ET. A live webcast will be accessible via the company’s Investors and News "Events and Presentations" page and will be available for replay after the event.
The presentation offers investors a real-time update opportunity and a post-event replay for later review.